Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
Samuel Yamshon(Cornell University), Tsiporah B. Shore(Cornell University), Michelle Pasciolla(NewYork–Presbyterian Hospital), Michelle Demetres(Cornell University), Mohammad Alhomoud(Memorial Sloan Kettering Cancer Center), Caitlin Gribbin(Cornell University), Zhengming Chen(Cornell University), Peter Martin(Northwestern University)
Cited by 10
Related Papers
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Vitamin C selectively kills <i>KRAS</i> and <i>BRAF</i> mutant colorectal cancer cells by targeting GAPDH
|Science|2015|907
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
|Blood|2015|408
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
|Journal of Clinical Oncology|2009|340